Study of the Functional Effects of Nusinersen in 5q-spinal Muscular Amyotrophy Adults (SMA Type 2 or 3 Forms)
study id #: NCT04576494
condition: Spinal Muscular Atrophy
status: Not yet recruiting
purpose:Spinal Muscular Atrophy (SMA) is an autosomal recessive disease caused by a mutation of exon 7, in 95% of cases, encoding the gene for the motor neuron survival protein called SMN1 (Survival Motor Neuron) located on chromosome 5q. Patients with an SMA-5q mutation suffer from progressive muscle deficiency and subsequent atrophy induced by degeneration of motor neurons in the spinal cord. Gene therapy is now available for the management of spinal muscular atrophy and nusinersen is the first approved treatment. Nusinersen has been granted marketing authorization in France since May 30, 2017. Nusinersen has a high level of medical service rendered (MSR) for types I, II, and III, but the improvement in medical service rendered (IMSR) is assessed as moderate for types I and II. For Type III, IMSR is not known.
intervention: Monthly assessments of functional motor abilities by a trained therapist, Nusinersen
results: https://clinicaltrials.gov/ct2/show/results/NCT04576494
last updated: February 04, 2022
-
Genetic Testing for Spinal Muscular Atrophyhttps://www.youtube.com/watch?v=7x_bumsC...
-
Once-Daily Risdiplam Beneficial in Patients With Types 2 and 3 SMA: LancetOnce-Daily Risdiplam is beneficial in pa...
-
FDA-Approved Treatment Provides Life-Saving Miracle for Girl With Spinal Muscular AtrophyAlex says her daughter made it to Norton...
-
Looking After Your Child Who Has Had a Recent Diagnosis of SMA Type 3Your child should receive care from memb...
-
Spinal Muscular Atrophy: From Rags to RichesThe aim of this paper is to provide a sh...
-
FDA Lifts Partial Clinical Hold on Novartis’ SMA Drug ProgrammeThe US Food and Drug Administration (FDA...
-
The SMA France National Registry: Already Encouraging ResultsSpinal muscular atrophy is a debilitatin...